Miiskin, a Copenhagen-based digital dermatology platform, has secured the prestigious Innobooster Grant to advance its AI-driven workflows and autonomous treatment plans for acne care. The company, which provides online dermatology consultations, aims to streamline doctor-patient interactions using artificial intelligence to reduce manual workloads and improve diagnostic efficiency.
Miiskin’s new AI Engine will assess skin conditions and generate personalized treatment plans in under a minute, with a goal of achieving 90% completion within one minute. The funding will enable Miiskin to enhance its platform, reducing patient wait times, improving treatment accessibility, and reducing physician burnout. By integrating medical-grade imaging and AI-assisted prescription tools, Miiskin aims to empower both dermatologists and patients while ensuring accurate and affordable care.
Miiskin, founded in 2022, is a cutting-edge digital dermatology platform that leverages artificial intelligence to transform the way patients access and receive dermatological care. Designed to streamline online consultations, Miiskin combines medical-grade imaging and AI technology to provide fast, accurate, and personalized skin assessments. By enabling dermatologists to diagnose and create individualized treatment plans for conditions like acne in under a minute, Miiskin enhances the efficiency of healthcare providers while improving patient outcomes. With a mission to revolutionize dermatology, Miiskin aims to expand access to affordable care, reduce doctor burnout, and positively impact the lives of millions globally, reaching 100 million patients by 2040.
The Innobooster project focuses on increasing the doctors efficiency and removing manual work when diagnosing and treating acne, the most prevalent skin disease worldwide using cutting-edge AI technology. With its new autonomous AI Engine, the Miiskin platform will be able to analyze and assess individuals with acne and generate individualized treatment plans for each patient—all in under 60 seconds.
The key goals of the project include achieving 90% completion of acne consultations within one minute, significantly improving treatment accessibility by utilizing an AI-assisted digital consultation model, and incorporating intelligent medication prescriptions directly on the platform. These advancements aim to streamline the dermatology process, making it faster and more efficient for both patients and healthcare providers.
“Winning the Innobooster is a testament to our commitment to revolutionizing dermatology care,” said Jon Friis, Founder and CEO of Miiskin. “Our AI-assisted workflows are designed to empower patients and dermatologists alike, delivering fast, accurate, and scalable treatment options that can be approved by the dermatologist with a single click.”
Miiskin’s AI-powered platform integrates medical-grade imaging and large language model (LLM) technology to assess disease severity and skin type with 90% accuracy. The platform generates personalized treatment plans and follow-up recommendations tailored to each patient’s needs, all while reducing manual workloads for healthcare providers. Through asynchronous consultations, Miiskin enhances efficiency and improves patient outcomes, enabling quicker, more accessible dermatological care.
Dr. Ryan Trowbridge, board-certified dermatologist and Miiskin advisor, said, “One of the key advantages of Miiskin’s new AI-driven solution is that it will be designed to support—not replace—dermatologists in diagnosing and treating acne,” says Dr. Trowbridge. “Miiskin’s AI engine will quickly analyze data and provide insights, but the dermatologist will always retain final authority over patient care. It’s a tool that elevates efficiency and accuracy and could lead to more affordable and accessible care for patients, simplifies interactions for providers, and preserves the opportunity for the medical professional to layer on their own expertise.”
The Miiskin platform has already facilitated thousands of patient consultations in the U.S., experiencing notable growth in both patient engagement and healthcare provider adoption. With the advancements under the Innobooster Grant initiative, Miiskin is poised to treat millions of patients worldwide, while significantly reducing manual worksteps and documentation for doctors. This initiative also aims to alleviate burnout among doctors and staff, enhance clinical efficiency, and minimize waiting times, ultimately expanding access to dermatology care on a global scale.
Click to read more funding news.
Read the orginal article: https://arcticstartup.com/miiskin-awarded-innobooster-grant/
